Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TAC Clear all
Completed Phase 1 Interventional

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

NCT00001249
View directory record Official record
Conditions
Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous
Interventions
Yttrium-90 radiolabeled anti-Tac antibody
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 10:15 PM EDT
Terminated Phase 4 Interventional Results available

Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis

NCT04002037
View directory record Official record
Conditions
Trigger Finger
Interventions
Triamcinolone Acetonide 40mg/mL, Triamcinolone Acetonide 10mg/mL, Dexamethasone 4 mg/ml
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 3, 2026, 10:15 PM EDT
Active, not recruiting Phase 3 Interventional

ZILRETTA in Subjects With Shoulder Osteoarthritis

NCT06269705
View directory record Official record
Conditions
Glenohumeral Osteoarthritis
Interventions
ZILRETTA, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Vestavia Hills, Alabama • Surprise, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 10:15 PM EDT
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema

NCT00367133
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Little Rock, Arkansas • Baldwin Park, California • Beverly Hills, California + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

LMB-2 to Treat Hairy Cell Leukemia

NCT00321555
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

NCT03002974
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb

NCT00398866
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 3, 2026, 10:15 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

NCT02988466
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

NCT00077922
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic
Interventions
LMB-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

NCT00093795
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Gemcitabine, Paclitaxel, Doxorubicin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stuart, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 3, 2026, 10:15 PM EDT
Not listed Phase 4 Interventional

Laryngeal Nerve Block for Chronic Cough

NCT05292677
View directory record Official record
Conditions
Laryngeal Nerve Block, Chronic Neurogenic Cough, Laryngeal Hypersensitivity
Interventions
Steroid/Anesthesia Mixture, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 3, 2026, 10:15 PM EDT
Terminated Not applicable Interventional Results available

Intraarticular Corticosteroid Therapy in Perthes Disease.

NCT01026909
View directory record Official record
Conditions
Legg-Calve Perthes Disease
Interventions
Aristospan 20mg
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
4 Years to 13 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 3, 2026, 10:15 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 4 Interventional Results available

C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain

NCT02095197
View directory record Official record
Conditions
Radicular; Neuropathic, Cervical, Neck Pain
Interventions
Triamcinolone 80mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 3, 2026, 10:15 PM EDT
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional

Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

NCT00100009
View directory record Official record
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

NCT04231318
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Cingal, Triamcinolone Hexacetonide (TH), Placebo
Drug
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 3, 2026, 10:15 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2005 · Synced Sep 3, 2026, 10:15 PM EDT
Withdrawn Not applicable Interventional

Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy

NCT06712290
View directory record Official record
Conditions
Rotator Cuff Tendinopathy
Interventions
celgene, Corticosteroid
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 3, 2026, 10:15 PM EDT